2022 World Conference on Lung Cancer (ePosters)-EP08.01-104. Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy

EP08.01-104. Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy

Back to course

Pdf Summary

This study aimed to investigate the relationship between baseline tumor size (BTS) and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immunotherapy. The researchers analyzed data from 159 patients who received immune checkpoint inhibitor (ICI) monotherapy or ICI in combination with chemotherapy between January 2016 and April 2021.<br /><br />The study found that in patients treated with ICI monotherapy, those with larger max BTS had worse progression-free survival (PFS) compared to those with smaller max BTS. However, this association was not observed in patients treated with ICI-chemo. Moreover, among patients with max BTS less than or equal to 50 mm, those treated with ICI monotherapy had worse PFS than those treated with ICI-chemo. However, this difference was not significant in patients with max BTS greater than 50 mm.<br /><br />The study also highlighted some limitations, including the small sample size and the presence of selection bias. Patients with more aggressive disease, younger age, better performance status, and no significant medical comorbidities were more likely to receive ICI-chemo.<br /><br />The results suggest that the predictive efficacy of max BTS may vary between patients treated with ICI monotherapy and ICI-chemo. Additionally, the benefit of adding chemotherapy to ICI in patients with PD-L1 expression greater than 50% remains unclear.<br /><br />Overall, this study contributes to the understanding of baseline tumor size as a prognostic and predictive factor for the efficacy of first-line immunotherapy in patients with advanced NSCLC. Further research is needed to validate these findings and explore other biomarkers for predicting the response to immune checkpoint inhibitors.

Asset Subtitle

Yuji Uehara

Meta Tag

Speaker Yuji Uehara

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

baseline tumor size

survival outcomes

advanced non-small cell lung cancer

first-line immunotherapy

immune checkpoint inhibitor

chemotherapy

progression-free survival

PD-L1 expression

prognostic factor

predictive factor